JPH2
TAUi001-A-1
General
Cell Line |
|
| hPSCreg name | TAUi001-A-1 |
| Cite as: | TAUi001-A-1 (RRID:CVCL_ZA78) |
| Alternative name(s) |
JPH2
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi035-A (NP0139-A, NP0139-3E) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-B (NP0139-B, NP0139-6C) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy UKKi035-C (NP0139-C, NP0139-24D) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Rare hypertrophic cardiomyopathy |
| Last update | 21st June 2021 |
| User feedback | |
Provider |
|
| Generator | Tampere University (TAU) |
| Derivation country | Finland |
External Databases |
|
| BioSamples | SAMEA6880675 |
| Cellosaurus | CVCL_ZA78 |
| Wikidata | Q98133171 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Fit4purpose-OOC project
Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
No
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA6880674 |
Ethics
Also have a look at the ethics information for the parental line
TAUi001-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
TAUi001-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||
| Feeder cells |
No |
||||||
| Passage method |
Enzymatically
Versene
|
||||||
| CO2 Concentration | 5 % | ||||||
| Medium |
mTeSR™ 1
Supplements
|
||||||
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
||||||
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
||||||
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| SOX2 |
Yes |
|||||
| NANOG |
Yes |
|||||
| ZFP42 (REX-1) |
Yes |
|||||
| C-MYC |
Yes |
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| KDR |
Yes |
| ACTC1 / alpha cardiac actinin |
Yes |
Protocol or reference
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
No
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Genetic modifications not related to a disease |
|
Login to share your feedback, experiences or results with the research community.